Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease (Q34997202)

5 August 2017

1 reference

title

Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

5 August 2017

1 reference

1 reference

1 reference

ChEBI release 2020-05-28

Dali Shukla

1

0 references

Brahmeshwar Mishra

object named as

Brahmeshwar Mishra

series ordinal

4

0 references

author name string

Subhashis Chakraborty

series ordinal

2

1 reference

PubMed ID

19678793

5 August 2017

Sanjay Singh

series ordinal

3

1 reference

PubMed ID

19678793

5 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Pharmacotherapy

5 August 2017

1 reference

5 August 2017

10

1 reference

5 August 2017

14

1 reference

5 August 2017

2343-2356

1 reference

Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations

5 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Anti-Inflammatory Potential of the Selective Phosphodiesterase 4 InhibitorN-(3,5-Dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), in Human Cell Preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

The potential of PDE4 inhibitors in respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Keynote review: phosphodiesterase-4 as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Functional KCa3.1 K+ channels are required for human lung mast cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Evaluation of in-vitro dissolution and in-vivo absorption for two different film-coated pellets of clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradyarrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Primary care of the patient with chronic obstructive pulmonary disease in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200667

10.1517/14656560903200667

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

19678793